Hospira continues to remain at risk for a consent decree as negative manufacturing updates, additional Form 483 observations and product recalls pile up, one analyst says. “Dramatic” quality improvement is likely needed to avoid a decree, RBC Capital Markets Analyst Shibani Malhotra said last month following Hospira’s quarter-three earnings call.
Drug GMP Report